Effcacy of combination of immunotherapy and chemotherapy as frst-line treatment for disseminated non-small cell lung cancer: a case report
- 7 April 2026
- journal article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (1)
Abstract
Background . Lung cancer is one of the most common cancers worldwide. Most newly diagnosed lung cancer patients present with distant metastases. Objective : to demonstrate a successful clinical case showing longterm overall and relapse-free survival rates in a patient with disseminated non-small cell lung cancer treated with a combination of immunotherapy and chemotherapy. Case presentation . A 72-year-old patient diagnosed with stage IV (T1bN0M1b) non-small cell lung asenocarcinoma of the right upper lobe achieved long-term disease stabilization using a combination of atezolizumab, bevacizumab and chemotherapy. The overall and progression-free survival was 38 months with a favorable safety profle. Conclusion . Despite current drug therapy options, the treatment of metastatic NSCLC remains challenging. This case report demonstrates the effcacy of atezolizumab in combination with bevacizumab and chemotherapy in patients with metastatic, untreated EGFR- and ALK -negative NSCLC negative for programmed cell death ligand 1 (PD-L1).Keywords
This publication has 6 references indexed in Scilit:
- Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsNature Communications, 2025
- Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAESMO Open, 2025
- Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysisFrontiers in Immunology, 2025
- Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Journal of Clinical Oncology, 2023
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trialJournal for ImmunoTherapy of Cancer, 2022
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCJournal of Thoracic Oncology, 2021